This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Curosurf (Poractant Alfa) industry.
How has the curosurf (poractant alfa) market size changed in recent years, and what is the outlook ahead?
The curosurf (poractant alfa) market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased demand for advanced medical solutions, demand for synthetic surfactants in hygiene products, an increase in healthcare awareness and improved access to healthcare, increased preference for easy cleanliness, which boosts synthetic surfactant sales, and an increase in healthcare awareness.
The curosurf (poractant alfa) market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising rates of premature births, increasing use of synthetic surfactants in agrochemicals, rising prevalence of chronic respiratory diseases, increasing healthcare expenditure, and increasing preference for respiratory infection. Major trends in the forecast period include adoption of microdosing strategies, integration of surfactant therapy, adoption of biologic and immunomodulatory therapies, shift toward sustainable and green surfactants, and focus on neonatal and pediatric care.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp
What are the top economic and technological drivers pushing curosurf (poractant alfa) market growth?
Increasing prevalence of respiratory disorders is expected to propel growth of the curosurf (poractant alfa) market going forward. Respiratory disorders refer to common conditions that affect the lungs and breathing, such as asthma, COPD, and lung cancer, leading to difficulty in breathing and reduced lung function. The prevalence of respiratory disorders is increasing due to rising air pollution, which exacerbates conditions such as asthma, and the aging population, which contributes to a higher incidence of age-related diseases such as COPD. Poractant alfa is used to treat neonatal respiratory distress syndrome by improving lung function and facilitating breathing in premature infants through administration via an endotracheal tube. For instance, in November 2023, according to the National Asthma Council, an Australia-based non-profit organization, in Australia, there were 467 asthma-related deaths recorded in 2022, comprising 299 females and 168 males. This figure represents an increase from the 355 deaths reported in 2021. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the curosurf (poractant alfa) market.
Growing Prevalence Of Premature Births Driving The Growth Of The Curosurf (Poractant Alfa) Market
The growing prevalence of premature births is expected to propel the growth of the Curosurf (poractant alfa) market going forward. Premature births refer to babies born before 37 weeks of gestation, as a full-term pregnancy typically lasts about 40 weeks. The rise in premature births is linked to older maternal age and the increased use of assisted reproductive technologies, which often lead to multiple pregnancies. Poractant alfa is used to treat premature infants with respiratory distress syndrome by reducing lung surface tension, helping the lungs stay open, and improving oxygen exchange. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, in 2022, the premature live birth rate in England and Wales was 7.9%, up from 7.5% in 2021. Therefore, growing prevalence of premature births is driving the growth of Curosurf (poractant alfa) market.
How is the curosurf (poractant alfa) market segmented by product, application, and end-user?
The curosurf (poractant alfa) market covered in this report is segmented –
1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace
3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders
4) By End User: Hospitals; Clinics; Ambulance Services
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-
What evolving trends are creating new opportunities in the curosurf (poractant alfa) market?
The key trend in the curosurf (poractant alfa) market is focusing on developing innovative solutions, such as novel inhaled gene therapy to address unmet needs in respiratory disorders. Novel inhaled gene therapy refers to a cutting-edge approach where therapeutic genes are delivered directly to the lungs via inhalation, typically through aerosolized particles or nanoparticles. For instance, in November 2024, AlveoGene, a UK-based developer of gene therapy, received Rare Pediatric Disease Designation (RPDD) from the FDA for AVG-002, a novel inhaled gene therapy targeting lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic disorder that leads to respiratory failure in infants. SP-B deficiency, caused by mutations in the SFTPB gene, currently has limited treatment options, primarily relying on lung transplantation. AVG-002 utilizes AlveoGene’s InGenuity platform to deliver a functional SP-B gene directly to the lungs, showing promising results in preclinical studies.
Which leading companies are dominating the curosurf (poractant alfa) market landscape?
Major companies operating in the curosurf (poractant alfa) market include Chiesi Farmaceutici S.p.A
Which geographic areas are expected to offer the highest growth opportunities in thecurosurf (poractant alfa) market?
North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Curosurf (Poractant Alfa) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19893
Need Customized Data On Curosurf (Poractant Alfa) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
